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HIGHLIGHTS  
1) Recent data on COVID-19 support that a later hyperinflammatory phase of COVID-19 has a 
decisive role in poor prognosis 
2) IL-1 inhibitor anakinra has shown to be highly effective in the treatment of cytokine storm syn-
dromes 
3) We present here the case of a patient with critical COVID-19 successfully treated with Anakinra 
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ABSTRACT 
Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant 
inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a corner-
stone treatment for hyperinflammatory diseases. We present here the case of a patient with critical 
COVID-19 successfully treated with IL-1 receptor antagonist (anakinra). 
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INTRODUCTION 
In December 2019, severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) 
was firstly discovered in Wuhan, China. Since then, Coronavirus Disease 19 (COVID-19) has risen 
to a global healthcare emergency, starting in late February 2020 in Northern Italy and rapidly be-
coming pandemic. The spectrum of symptomatic SARS-CoV-2 infection ranges from mild to criti-
cal. While the former accounts for 80% of cases, severe disease with acute respiratory distress syn-
drome (ARDS) and critical disease with respiratory failure and/or multiple organ dysfunction are 
diagnosed in 15-30% and 5% of COVID-19 patients, respectively (1). In the first month of COVID-
19 outbreak in Northern Italy, intensive care unit (ICU) admission represented 12% of all COVID-
19 patients and 16% of those hospitalized (2). Overall, COVID-19 estimated case fatality rate rang-
es from 2.3% in China to 7.2% in Italy (3). However, in China’s virus pandemic epicentre during 
the early stage of COVID-19 outbreak, the in-hospital overall lethality rate was higher (28%), and 
rose up to 62-97% in severely-ill patients requiring mechanical ventilation. (4). As of March 25 
2020, in Lombardy, Italy, 1591 patients were admitted in ICUs, of them, 405 (26%) had died in 
ICU, 256 (16%) had been discharged from the ICU, while 920 patients (58%) were still in the ICU 
(5).    
Early data on changes in clinical and laboratory findings over time demonstrated that levels of d-
dimer, high-sensitivity cardiac troponin I, serum ferritin, lactate dehydrogenase, and interleukin 
(IL)-6 are higher in non-survivors compared with survivors throughout the clinical course, and their 
increase paralleled illness deterioration (6).  
Previous reports demonstrated that a cytokine storm occurs in SARS-CoV-1 and Middle-East Res-
piratory Syndrome (MERS)-CoV infection, with high levels of IL-1β, IL-6, IL-12, tumor necrosis 
factor (TNF)α, interferon (INF)- and INF- induced chemokine CXCL10 (7). Recent data on 
COVID-19 support that a relevant inflammatory cytokine storm is associated with severity of dis-
ease. (8)   
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The IL-1 receptor antagonist (anakinra) is a cornerstone treatment for hyperinflammatory condi-
tions such as Still’s disease, and has been shown to be highly effective in the treatment of cytokine 
storm syndromes, including macrophage activation syndrome and cytokine release syndrome (9).  
Anakinra has a very safe profile and high dosages have been used even in patients with severe viral 
infection (EBV, H1N1 and Ebola) (10).  
We present here the case of a patient with critical COVID-19 successfully treated with Anakinra.  
 
CASE REPORT 
On February 28th, 2020 an otherwise healthy 50 year-old man was admitted to the local 
Hospital in Crema, Lombardy because of fever and dyspnea. Infection with SARS-CoV-2 was con-
firmed by RT- PCR on nasopharyngeal swab and chest computerized tomography scan showed bi-
lateral ground glass opacities. The patient was put on non-invasive ventilation and antiviral therapy 
with lopinavir/ritonavir plus hydroxychloroquine was started. At day 3, his conditions worsened 
requiring ICU admission at our Hospital for invasive mechanical ventilation and hemodynamic 
support. On ICU admission, the ratio of arterial oxygen partial pressure to fractional inspired oxy-
gen (PaO2/FiO2) was 160 on pressure control ventilation, with positive end expiratory pressure 
(PEEP) 12 and FiO2 50%. High levels of acute phase reactants and progressive liver cholestatic in-
jury were observed (Table 1). Hepatic involvement with liver enzymes higher more than five-folds 
their upper limits contraindicated treatment with remdesivir or tocilizumab. At day 10, considering 
the patient’s critical conditions (PaO2/FiO2 85, volume control ventilation PEEP 14 FiO2 50%) and 
the hyperferritinemic inflammatory status with ferritin levels more than 3000 ng/ml, use of off-label 
anakinra was considered and started with the following dosage schedule: 200mg intravenously fol-
lowed by 100 mg every 6 hours subcutaneously. Lopinavir/ritonavir and hydroxychloroquine were 
interrupted and no other immunosuppressive or immunomodulatory drug, including glucocorticoids 
or immunoglobulins, was started. In the next 72 hours, a sharp reduction of inflammatory markers 
and ferritin, an increase in lymphocyte count and a significant reduction of liver enzymes were ob-
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served (Table 1). Respiratory parameters improved by day 13 (PaO2/FiO2 270, pressure control 
ventilation PEEP 10 FiO2 30%), followed by a favourable radiographic evolution. At day 18 the 
patient was discharged from the ICU.  
In the following days, respiratory function progressively improved. On day 21, 4 days after ICU 
discharge, the patient became febrile with increase in C-reactive protein levels and no alteration in 
ferritin levels. Considering the persistent improvement in respiratory function and on suspicion of 
central venous catheter-related bacteremia, anakinra was stopped. Intravenous catheter was re-
moved and empiric antibiotic treatment started with vancomycin plus piperacillin/tazobactam, mod-
ified 2 days later to cefazolin according to the identification of methicillin-sensitive Staphylococcus 
aureus in blood culture. A complete and prompt response to antibiotic treatment was observed with 
normalization of acute phase reactants. Patient was discharged from the hospital at day 29 in 
healthy conditions and normal oxygen saturation on room air. 
 
DISCUSSION 
To our knowledge, this is the first report of a critical case of COVID-19 effectively treated with an-
akinra. 
Current management of COVID-19 is supportive, as respiratory failure from ARDS is the leading 
cause of mortality. Vaccines and approved targeted therapies for SARS-CoV-2 infection are still 
lacking and a multitude of compounds are now under investigation . The need to urgently identify 
an effective approach to manage COVID-19 led to the testing of existing antiviral drugs commonly 
used for other viral infections (i.e., interferon, ribavirin, and lopinavir-ritonavir), at present with 
controversial results (11). Remdesevir is a promising novel nucleotide analogue with in vitro activi-
ty against SARS-CoV-2 and proved activity against SARS- CoV-1 and MERS-CoV both in vitro 
and in animal studies (12). 
Recently a cytokine storm resembling secondary haemophagocytic lymphohistiocytosis 
(sHLH) has been suggested to drive a later hyperinflammatory stage of COVID-19, with a decisive 
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role in poor prognosis (13). sHLH is a hyperinflammatory syndrome characterised by life-
threatening hypercytokinaemia leading to multiorgan failure.  A cytokine profile resembling sHLH, 
characterized by increased levels of  IL-2, IL-7, granulocyte-colony stimulating factor, INF-γ, 
CXCL10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and TNFα 
was described in severe COVID-19 (13). Predictors of mortality from a retrospective, multicentre 
study of 190 confirmed COVID-19 cases in Wuhan, China, included elevated ferritin (mean 1435·3 
mcg/L in non-survivors vs 503·2 mcg/L in survivors) and IL-6 levels (5), suggesting that higher 
mortality rates may be associated with a virally driven hyperinflammation. 
The possible role of anti-cytokine treatment with IL-6 inhibitor (tocilizumab) in respiratory 
failure associated to COVID-19 has been recently proposed (14). In inflammatory cytokine storms, 
IL-1 is a key effector and its role in promoting pro-inflammatory cytokines, including IL-6, is well 
known (15). Indeed, IL-1 inhibitor anakinra has shown to be highly effective in the treatment of cy-
tokine storm syndromes (15) and has already been proven safe in patients with sHLH associated to 
viral infections such as EBV, H1N1 and Ebola (10). Its short half-life makes it a widely drug to be 
use in clinical practice also in critically ill patients, in the eventuality of overcoming situations in 
which a prompt treatment interruption is required such as bacteraemia as described above.   
This first report suggests that in the cytokine storm occurring during severe COVID-19, IL1 inhibi-
tion may represent a safe and promising strategy to reduce inflammation preventing multi-organ 
dysfunction and an appropriate tailored treatment strategy is crucial.  
Further larger cohort observations are needed to confirm the possible association with positive clin-
ical outcomes. To date, May the 5th 2020, 12 clinical trials on anakinra in COVID-19 patients are 
registered on ClinicalTrials.gov, 7 of them recruiting patients. These ongoing studies will provide 
key information on safety and efficacy of anakinra in the hyperinflammatory response to SARS-
CoV-2.  
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Table 1. Course of laboratory tests and respiratory parameters over time  
 
 Day 0 Day 3 Day 9 Day 10 Day 11 Day 13 Day 18 Day 21 Day 29 
 Hospital 
admission 
ICU  
admission 
 Anakinra  
administration 
  Discharg 
from ICU 
Stop  
Anakinra 
Discharg 
from 
Hospital 
WBC count, 
x109/l 
4.9 6.9 5.8 9.7 10.8 10.9 10.6 9.07 6.14 
Lymphocyte 
count, x109/l 
0.6 0.3 0.5 1.0 0.6 0.9 1.0 1.17 1.67 
Hemoglobin, 
g/dl 
11.5 9.9 9.8 10.4 9.9 9.1 9.1 9 10.6 
PLT count 
x109/l 
191 215 362 444 429 473 507 513 330 
Ferritin, 
ng/ml 
   3042 1936 1040 648 738 497 
CRP, mg/dl 10.5 20.4 8.8 8.6 11.3 3.2 2.4 4,4 0.3 
AST, U/l   188 182 94 43 29 29  
ALT, U/l 18 20 224 384 307 188 90 73 11 
GGT, U/l 48 107 276 586 562 442 344 299 110 
Bilirubin, 
mg/dl 
  2.1 2.0 0.9 0.6 0.8 0.92 0.66 
LDH, U/l 300 289 334 334 267 219 233 278 180 
Creatinine, 
mg/dl 
0.8 0.9 0.8 0.7 0.5 0.6 0.6 0.6 0.65 
Fibrinogen, 
mg/dl 
472 707 881  929 618 506 426  
D-dimer, ug/l 423 429 837  1834 1352 4684 4082 1025 
PaO2/FiO2 160 182 109 85 85 280 310  Oxygen 
saturation 
97% on 
room air  
 
 
 
WBC: white blood cell; PLT: platelet count; CRP: C-reactive protein; AST: aspartate aminotransferase; ALT: alanine ami-
notransferase; GGT: gamma glutamyl transferase; LDH: lactic dehydrogenase; PaO2: arterial oxygen partial pressure; 
FiO2: fraction of inspired oxygen.  
